HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SH7129

contain three recognition ligands conjugated to an identical linker scaffold composed of three D-lysines and three mini-PEGs with a Biotin tag

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Balhorn, Monique Cosman: 1 article (09/2020)
2.	Balhorn, Rod: 1 article (09/2020)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2020 - "The aim of this study was to determine how frequently the HLA-DRs targeted by SH7139 are expressed by different subtypes of non-Hodgkin's lymphoma and by other solid cancers that have been reported to express HLA-DR. Binding studies conducted with SH7129, a biotinylated analog of SH7139, reveal that more than half of the biopsy sections obtained from patients with different types of non-Hodgkin's lymphoma express the HLA-DRs targeted by SH7139. " 09/01/2020 - "The high frequency with which SH7129 was observed to bind to these cancers suggests that many patients diagnosed with B-cell lymphomas, myelomas, and other non-hematological cancers should be considered potential candidates for new therapies such as SH7139 that target HLA-DR-expressing tumors."
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/01/2020 - "The aim of this study was to determine how frequently the HLA-DRs targeted by SH7139 are expressed by different subtypes of non-Hodgkin's lymphoma and by other solid cancers that have been reported to express HLA-DR. Binding studies conducted with SH7129, a biotinylated analog of SH7139, reveal that more than half of the biopsy sections obtained from patients with different types of non-Hodgkin's lymphoma express the HLA-DRs targeted by SH7139. "
3.	B-Cell Lymphoma (Lymphoma, B Cell) 09/01/2020 - "The high frequency with which SH7129 was observed to bind to these cancers suggests that many patients diagnosed with B-cell lymphomas, myelomas, and other non-hematological cancers should be considered potential candidates for new therapies such as SH7139 that target HLA-DR-expressing tumors."

Related Drugs and Biologics

1.	HLA-DR Antigens (HLA-DR)
2.	SH7139

Related Therapies and Procedures

1.	Therapeutics